Broadening inclusion of vulnerable populations in HIV vaccine trials

Expert Review of Vaccines

Volumn 7, Issue 2, 2008, Pages 259-268

  Lau, Chuen Yen ^a   Cardinali, Massimo ^a   Sato, Paul A ^a   Fix, Alan ^a   Flores, Jorge ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adolescents; Clinical trials; HIV; Infants; Injection drug users vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; DRUG USE; ETHICS; HEALTH SERVICE; HIGH RISK INFANT; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYGIENE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; INJECTION DRUG USER; LEGAL ASPECT; NUTRITION; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCIENCE; SEXUALLY TRANSMITTED DISEASE;

ADOLESCENT; ADULT; AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VULNERABLE POPULATIONS;

EID: 40549117920     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.2.259     Document Type: Review

References (54)

1. John-Stewart G, Mbori-Ngacha D, Epkini R. Breast-feeding and transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35, 196-202 (2004).
2. Breastfeeding and HIV International Transmission Study Group (BHITS). Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J. Infect. Dis. 189, 2154-2166 (2004).
3. De Cock KM, Fowler MG, Mercier E et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice JAMA 283, 1175-1182 (2000).
4. Nduati R, John G, Mbori-Ngacha D et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283(9), 1167-1174 (2000).
5. Safrit JT. HIV vaccines in infants and children: past trials, present plans and future perspectives. Curr. Mol. Med. 3, 303-312 (2003). •bull; Reviews the early history of HIV clinical trials in infants.
6. Gall SA. Maternal immunization to protect the mother and neonate. Expert Rev. Vaccines 4, 813-818 (2005).
7. Adkins B. Neonatal T cell function. J. Pediatr. Gastroenterol. Nutr. 40, S5-S7 (2005).
8. Hofmann-Lehmann R, Rasmussen RA, Vlasak J et al. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J. Med. Primatol. 30(4), 190-196 (2001).
9. Lambert JS. HIV vaccines in infants and children. Pediatric Drugs 7, 267-276 (2005).
10. Rasmussen RA, Hofmann-Lehman R, Montefiori DC et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J. Med. Primatol. 31, 40-60 (2002).
11. Van Rompay KK, Greenier JL, Cole KS. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77,179-190 (2003).
12. Van Rompay KK, Abel K, Lawson JR et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38,124-134 (2005).
13. Lambert JS, McNamara J, Katz SL et al. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19, 451-461 (1998).
14. Borkowsky W, Wara D, Fenton T et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J. Infect. Dis. 181, 890-896(2000).
15. McFarland E, Johnson D, Muresan P et al. Safety and cell-mediated immune responses to prime-boost immunization with ALVAC HIV vaccine and Aidsvax B/B in newborns of HIV-infected mothers (PACTG 326). Presented at: Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005.
16. Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine 21, 3389-3392 (2003).
17. Shetty AK. Perinatally acquired HIV-1 infection: prevention and evaluation of HIV-exposed infants. Semin. Pediatr. Infect. Dis. 16, 282-295 (2005).
18. Zheng B-J, Ng M-H, He L-F et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 19(30), 4219-4225 (2001).
19. US CDC. Deaths: preliminary data for 2002. In: National Vital Statistics Reports. 54 (19), 1-52 (2006).
20. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int. Immunopharmacol. 1, 983-993 (2001).
21. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20, 483-494 (2006).
22. R. Steinbrook. One step forward, two steps back - will there ever be an AIDS vaccine? N. Engl. J. Med. 357(26), 2653-2655 (2007).
23. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16, 266-271 (1997).
24. Buchbinder SB, Li J, Mehrotra D et al. Risk behavior change among high risk volunteers enrolled in the STEP HIV vaccine efficacy trial (Merck V520 Protocol 023 / HVTN 502). Presented at: AIDS Vaccine 2007. Seattle, WA, USA, 20-23 August 2007.
25. Kapogiannis BG, Lee SS. Rolling up our sleeves now to reap the benefits later: preparing the community for an adolescent HIV vaccine. Curr. Opin. HIV AIDS 2, 375-384 (2007).
26. Strode A, Grant C, Slack C, Mushariwa M. How well does South Africa's National Health Act regulate research involving children? South Africa Med. J. 95, 265-268 (2005). •• Discusses regulatory and ethical issues pertaining to research involving children, including adolescents.
27. Martins RM, Bensabath G, Arraes LC et al. Multicenter study of the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem. Inst. Oswaldo Cruz 99, 865-871(2004).
28. Heron LG, Chant KG Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 20, 3472-3476 (2002).
29. Levie K, Beran J, Collard F et al. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and a three dose schedule in adolescents aged 12-15 years. Vaccine 20, 2579-2584 (2002).
30. Foy HM, Cooney MK, Allan ID, et al. Influenza B virus vaccines in children and adults: adverse reactions, immune response, and observation in the field. J. Infect. Dis. 143,700-706 (1981).
31. Nolan T, Block L, Reisinger KS et al. Comparison of the immunogenicity and tolerability of a preventive quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine in male and female adolescents and young adults women. Presented at: 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Valencia, Spain, 18-20 May 2005.
32. UNAIDS/WHO. AIDS epidemic update, December 2004. Available on request from: UNAIDS, 1211 Geneva 27, Switzerland (2004).
33. Panda S. HIV in IDUs: should we bother? Int. J. Drug Policy. 14, 83-85 (2003).
34. WHO-UNAIDS HIV Vaccine Advisory Committee. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. AIDS 15, W1-W25 (2001).
35. Aceijas C, Stimson GV, Hickman M, Rhodes, T. Global overview of injecting drug use and HIV infection among injection drug users. AIDS 18, 2295-2303 (2004). •• Highlights global dimensions of the HIV epidemic in injection drug users (IDUs).
36. Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect. Dis. 7(10), 667-674 (2007).
37. Lu Y, Brosio P, Lafaile M et al. Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. J Virol. 70, 3045-3056 (1996).
38. Johnson RP, Lifson JD, Czajak, SC et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol. 73, 4953-4961(1999).
39. Hu DJ, Subbarao S, Vanichseni S et al. Higher viral loads and other risk factors associated with HIV-1 seroconversion during a period of high incidence among injection drug users in Bangkok. J. AIDS 30, 240-247 (2002).
40. Thapinta D, Jenkins RA. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand. Contemp. Clin. Trials 28, 409-22 (2007).
41. Van Griensven F, Keawkungwal J, Tappero J et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 18, 295-301(2004).
42. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH harmonization tripartite guidelines: E6 Guidelines for Good Clinical Practice (1996) www.ifpma.org/pdfifpma/e6.pdf
43. US Code of Federal Regulations. Title 21; Food and Drug Administration (Part 56) Institutional Review Boards (1999) www4.law.cornell.edu/cfr/21p56.html
44. UNAIDS/WHO. AIDS epidemic update, December 2005 (2005) www.unaids.org/en/default.asp
45. UNAIDS/WHO. AIDS epidemic update, December (2007) www.unaids.org/en/ default.asp
46. WHO Consensus Statement. HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on prevention of HIV infections in pregnant women, mothers and their infants (2006) www.who.int/child-adolescenthealth/New_Publications/NUTRITION/con sensus_statement.pdf •• Owing to advantages of breastfeeding, methods other than discontinuation of breastfeeding (such as vaccination) are needed to prevent MTCT.
47. HIV Prevention Trials Network study 027 Protocol Team. A Phase I study to evaluate the safety and immunogenicity of ALVAC-HIV vCP1521 in infants born to HIV-1 infected women in Uganda (2005) www.hptn.org/Web%20Documents/ HPTN_Protocols/HPTN027v2.pdf
48. US FDA. Guidance for industry: development of preventive HIV vaccines for use in pediatric populations (2006) www.fda.gov/cber/gdlns/pedhiv.htm
49. Brookes H, Shisana O, Richter L. The National Household HIV Prevalence Risk Survey of South African children. HSRC Press (2004) www.hsrcpublishers.ac. za
50. HIV Vaccine Trial Network. Vaccines in development (2007) http://chi.ucsf.edu/vaccines/
51. US Code of Federal Regulations. Title 45; Food and Drug Administration (Part 46). Basic HHS policy for protection of human research subjects (2002) http://edocket.access.gpo.gov/cfr_2002/octqtr/45cfr46.101.htm •• Contains the complex requirements for informed consent in children, including adolescents.
52. UNAIDS Press Backgrounder for world AIDS day, 1999. Structural collapse sets the scene for the rapid spread of HIV/AIDS among young people in Eastern Europe http://gbgm-umc.org/programs/wad99/easteuro2.html.
53. Open Society Institute. Breaking down barriers. Lessons in providing HIV treatment to injection drug users (2004) www.soros.org/initiatives/health/focus/ ihrd/articles_publications/publications/arv_idus_20040715 •• Highlights challenges likely to occur during research involving IDUs.
54. Zhang Y, Fu X, Wang Z, Davis C, Burris S. The social and legal risks for injection drug users participating in HPTN 058 in Urumqi and Heng Chien, China (2007) www.hptn.org/web%20documents/HPTN058/RapidPolicyAssessments/HPTN058RPAF inal%20Report-China.pdf.